These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 30544079)

  • 1. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
    Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
    Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature.
    Grebenciucova E; Reder AT; Bernard JT
    Mult Scler Relat Disord; 2016 Sep; 9():158-62. PubMed ID: 27645366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryptococcal meningoencephalitis in an IgG
    Wienemann T; Müller AK; MacKenzie C; Bielor C; Weyers V; Aktas O; Hartung HP; Kremer D
    BMC Neurol; 2020 Apr; 20(1):158. PubMed ID: 32340606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
    Christopher KL; Elner VM; Demirci H
    Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod.
    Harirchian MH; Poursadeghfard M; Sadeghipour A; Kamali H; Sarraf P
    Mult Scler Relat Disord; 2020 Jun; 41():102021. PubMed ID: 32126512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
    Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
    J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
    Walker S; Brew B
    J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports.
    Zanetta C; Filippi M; Moiola L
    Neurol Sci; 2021 May; 42(Suppl 1):9-13. PubMed ID: 33904006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
    Sharim J; Tashjian R; Golzy N; Pouratian N
    J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of Fingolimod-associated Cryptococcal Meningitis.
    Darazam IA; Rabiei MM; Moradi O; Gharehbagh FJ; Roozbeh M; Nourinia R; Hatami F; Shojaei M; Lotfollahi L
    Curr HIV Res; 2022; 20(4):337-342. PubMed ID: 35770404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
    Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
    Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryptococcal meningitis causing obstructive hydrocephalus in a patient on fingolimod.
    Pham C; Bennett I; Jithoo R
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28687690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.
    Thomas K; Proschmann U; Ziemssen T
    Expert Opin Pharmacother; 2017 Oct; 18(15):1649-1660. PubMed ID: 28844164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
    Tichá V; Kodým R; Počíková Z; Kadlecová P
    Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.
    Ziemssen T; Kern R; Cornelissen C
    BMC Neurol; 2016 Aug; 16():129. PubMed ID: 27502119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.
    Navardi S; Sahraian MA
    Mult Scler Relat Disord; 2018 Apr; 21():69-70. PubMed ID: 29474980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis.
    Cuascut FX; Alkabie S; Hutton GJ
    Mult Scler Relat Disord; 2021 Aug; 53():103072. PubMed ID: 34139459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.